Effect of Different Nail Penetration Enhancers in Solid Lipid Nanoparticles Containing Terbinafine Hydrochloride for Treatment of Onychomycosis

被引:8
作者
Abobakr, Fatma E. [1 ]
Fayez, Sahar M. [2 ]
Elwazzan, Vivian S. [1 ]
Sakran, Wedad [3 ]
机构
[1] Natl Org Drug Control & Res NODCAR, Dept Pharmaceut, Cairo, Egypt
[2] October 6th Univ, Dept Pharmaceut & Ind Pharm, Fac Pharm, Cairo, Egypt
[3] Helwan Univ, Dept Pharmaceut & Ind Pharm, Fac Pharm, Cairo, Egypt
关键词
nail penetration enhancers (nPEs); terbinafine HCl (TFH); solid lipid nanoparticles (SLNs); onychomycosis; ex vivo transungual drug uptake;
D O I
10.1208/s12249-020-01893-9
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Onychomycosis is considered a stubborn nail fungal infection that does not respond to conventional topical antifungal treatments. This study aimed to develop and characterize novel solid lipid nanoparticles (SLNs) formulae containing terbinafine HCl (TFH) and loaded with different nail penetration enhancers (nPEs). Three (nPEs) N-acetyl-L-cysteine, thioglycolic acid, and thiourea were used. Characterization of the prepared formulae was done regarding particle size, zeta potential, polydispersity index (PDI), entrapment efficiency (EE%), physical stability, in vitro release study, infrared (FT-IR), and their morphological structures. The selected formulae and the marketed cream Lamifen (R) were compared in terms of their antifungal activity against Trichophyton rubrum as well as their nail hydration and their drug uptake by the nail clippers. Thiourea was the nPE of choice; formulae (N2 and N8), with thiourea, were considered the optimum TFH SLNs containing nPEs. They were selected for their optimum particle size of 426.3 +/- 10.18 and 450.8 +/- 11.45 nm as well as their highest EE% of 89.76 +/- 1.25 and 90.35 +/- 1.33, respectively. The in vitro microbiological screening of the antifungal activity of these two formulae showed significantly larger zones of inhibition in comparison with the marketed product. The ex vivo screening of the drug uptake of the two selected formulae was significantly higher than that of the marketed product. The nPE formulae present a very promising option as they showed optimum physicochemical characterization with high antifungal activity and high drug uptake as well as good nail hydration effect.
引用
收藏
页数:12
相关论文
共 50 条
[1]  
Abobakr F.E., 2019, Int. J. Pharm. Pharm. Sci., V11, P16, DOI [10.22159/ijpps.2019v11i12.35560, DOI 10.22159/IJPPS.2019V11I12.35560]
[2]   Onychomycosis: Potential of Nail Lacquers in Transungual Delivery of Antifungals [J].
Akhtar, Nida ;
Sharma, Hemlata ;
Pathak, Kamla .
SCIENTIFICA, 2016, 2016
[3]  
[Anonymous], 2012, J PHARM RES OPIN
[4]  
[Anonymous], 2019, US PHARMACOPEIA 42 N, V2, P4233
[5]   Topical antifungal drugs for the treatment of onychomycosis: an overview of current strategies for monotherapy and combination therapy [J].
Baran, R ;
Kaoukhov, A .
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2005, 19 (01) :21-29
[6]   Microemulsion-Based Gel of Terbinafine for the Treatment of Onychomycosis: Optimization of Formulation Using D-Optimal Design [J].
Barot, Bhavesh S. ;
Parejiya, Punit B. ;
Patel, Hetal K. ;
Gohel, Mukesh C. ;
Shelat, Pragna K. .
AAPS PHARMSCITECH, 2012, 13 (01) :184-192
[7]   Novel nail penetration enhancer containing vesicles "nPEVs'' for treatment of onychomycosis [J].
Bseiso, Eman A. ;
Nasr, Maha ;
Sammour, Omaima A. ;
Abd El Gawad, Nabaweya A. .
DRUG DELIVERY, 2016, 23 (08) :2813-2819
[8]  
Choudhari Y.M., 2014, J. Nanopharm. Drug Deliv, V1, P376, DOI [10.1166/jnd.2013.1031, DOI 10.1166/JND.2013.1031]
[9]   Hydration of nail plate: A novel screening model for transungual drug permeation enhancers [J].
Chouhan, P. ;
Saini, T. R. .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2012, 436 (1-2) :179-182
[10]   Effect of Penetration Enhancers on Drug Nail Permeability from Cyclodextrin/Poloxamer-Soluble Polypseudorotaxane-Based Nail Lacquers [J].
Cutrin-Gomez, Elena ;
Anguiano-Igea, Soledad ;
Begona Delgado-Charro, M. ;
Luis Gomez-Amoza, Jose ;
Otero-Espinar, Francisco J. .
PHARMACEUTICS, 2018, 10 (04)